Poland· PL-100463504
Aspaveli
A pegcetacoplan product containing pegcetacoplanum, registered in Poland by Swedish Orphan Biovitrum AB (publ). The same ATC class is registered in 12 of our 19 countries.
Checked against URPL (Poland) on
Informational only — not a medical device.
Where it is registered
Pegcetacoplan is registered in 12 of 19 countries.
Countries holding a registration under ATC L04AJ03 (pegcetacoplan), each read from that country’s own register.
- This record: Poland, from URPL (Poland)
- 8 of them publish a price we can compare per daily dose
Pegcetacoplan · ATC L04AJ03
12 / 19 countries
- Belgiumprice
- Canada
- Czechiaprice
- Denmark
- Finlandprice
- Icelandprice
- Netherlands
- Norwayprice
- Polandprice
- Switzerlandprice
- United Kingdom
- United Statesprice
The record
At a glance
URPL (Poland)- Active substance
- Pegcetacoplanum
- Manufacturer
- Swedish Orphan Biovitrum AB (publ)
- Country
- Poland (PL)
- ATC code
- L04AJ03
- ATC class
- Pegcetacoplan
- Defined daily dose
- 0.3 g, P
- Reimbursed
- Not published by this register
- Source register
- URPL (Poland)
- Last checked
- September 27, 2026
Packs & prices · 4
- gtin07350031443950
- gtin07350031443295
- gtin07350031443967
- gtin07350031443301
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Same medicine, other countries
Pegcetacoplan in 14 other countries
What each register calls a product with the same active substance — salts and hydrates count as the same.
- SwitzerlandAspaveli
- United StatesEmpaveliApellis Pharmaceuticals, Inc.
- CzechiaASPAVELISwedish Orphan Biovitrum AB (publ), Stockholm
- FinlandASPAVELISwedish Orphan Biovitrum AB (publ)
- FranceASPAVELI 1080 mg, solution pour perfusionSWEDISH ORPHAN BIOVITRUM (SUEDE)
- BelgiumAspaveli 1080 mgSwedish Orphan Biovitrum (Publ)
- IrelandASPAVELI 1 080 mg solution for infusionApellis Ireland Limited
- IcelandASPAVELI*Swedish Orphan Biovitrum AB (publ)
Authorised across Europe · EMA
The same active substance is authorised in 3 EEA countries. Names it is sold under:
- Iceland · Aspaveli
- Liechtenstein · Aspaveli
- Norway · Aspaveli
Source: European Medicines Agency, Article 57 product data.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of URPL (Poland). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/98c9bf7a-7f47-48e5-9992-61ffc9b13322 GET /v1/drugs/98c9bf7a-7f47-48e5-9992-61ffc9b13322?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"form": "Roztwór do infuzji",
"source": "urpl",
"strength": "54 mg/ml",
"packaging": "07350031443950 ¦ Rpz ¦ EU/1/21/1595/001 ¦ 143475\n1 fiol. 20 ml\n¦ UR/Z/4b/103/22 - 07350031443295\n07350031443967 ¦ Rpz ¦ EU/1/21/1595/002 ¦ 143476\n8 fiol. 20 ml\n¦ UR/Z/4b/104/22 - 07350031443301",
"substance": "Pegcetacoplanum 1080 mg",
"common_name": "Pegcetacoplanum",
"pl_product_id": "100463504",
"pozwolenie_nr": null,
"auth_procedure": "CEN",
"authorisation_validity": null
}See everything about pegcetacoplan.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.